Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

My burning issues in aggressive Non Hodgkin’s Lymphoma

My burning issues in aggressive Non Hodgkin’s Lymphoma Combined-modality treatment with chemo-immunotherapy and radiotherapy produces excellent outcomes in early-stage, non-bulky diffuse large B‑cell lymphoma, and reducing toxicity of therapy is a major concern, especially in elderly patients. In a recent trial, elderly patients with non-bulky (<7.5 cm) in complete metabolic remission after four courses of therapy (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone [R‑CHOP-14] based) were spared additional chemotherapy and went on to receive four cycles of rituximab only, while all other patients continued on chemo-immunotherapy. The 2‑year overall survival was 98%, which matches historical controls. In another analysis from the same trial, elderly patients with bulky disease in positrone emission tomography (PET) based CR (complete remission) after six cycles of chemo-immunotherapy were spared radiotherapy, while PET-positive patients were irradiated. This approach resulted in a significant reduction (42%) of radiotherapy compared to historical controls without compromising efficacy. Radiotherapy could also be omitted in patients of any age with limited stage, non-bulky disease in another trial, with a 5-year event-free survival of 89% and an overall survival of 92%. Another burning issue is enhancing efficacy in relapsed and refractory diffuse large B‑cell lymphoma. Arguably the most exciting approach in this area is chimeric-antigen-receptor T‑cell therapy. Recent trials have shown nearly 10-fold increases in complete responses compared to historical controls, and most importantly, a high percentage (40%) of durable remissions after one year of follow-up. As in other advances in immunotherapy, toxicity is a major concern. Cytokine release syndrome occurs frequently (1–18% grade 3–4) and management is complex, sometimes requiring admission to intensive care and often including the interleukin-6 receptor antibody tocilizumab. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

My burning issues in aggressive Non Hodgkin’s Lymphoma

Download PDF
3 pages

Loading next page...
 
/lp/springer_journal/my-burning-issues-in-aggressive-non-hodgkin-s-lymphoma-1g5oGRXsJr
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-018-0413-1
Publisher site
See Article on Publisher Site

Abstract

Combined-modality treatment with chemo-immunotherapy and radiotherapy produces excellent outcomes in early-stage, non-bulky diffuse large B‑cell lymphoma, and reducing toxicity of therapy is a major concern, especially in elderly patients. In a recent trial, elderly patients with non-bulky (<7.5 cm) in complete metabolic remission after four courses of therapy (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone [R‑CHOP-14] based) were spared additional chemotherapy and went on to receive four cycles of rituximab only, while all other patients continued on chemo-immunotherapy. The 2‑year overall survival was 98%, which matches historical controls. In another analysis from the same trial, elderly patients with bulky disease in positrone emission tomography (PET) based CR (complete remission) after six cycles of chemo-immunotherapy were spared radiotherapy, while PET-positive patients were irradiated. This approach resulted in a significant reduction (42%) of radiotherapy compared to historical controls without compromising efficacy. Radiotherapy could also be omitted in patients of any age with limited stage, non-bulky disease in another trial, with a 5-year event-free survival of 89% and an overall survival of 92%. Another burning issue is enhancing efficacy in relapsed and refractory diffuse large B‑cell lymphoma. Arguably the most exciting approach in this area is chimeric-antigen-receptor T‑cell therapy. Recent trials have shown nearly 10-fold increases in complete responses compared to historical controls, and most importantly, a high percentage (40%) of durable remissions after one year of follow-up. As in other advances in immunotherapy, toxicity is a major concern. Cytokine release syndrome occurs frequently (1–18% grade 3–4) and management is complex, sometimes requiring admission to intensive care and often including the interleukin-6 receptor antibody tocilizumab.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: May 28, 2018

References

  • Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B‑cell lymphoma: Southwest Oncology Group study 0014
    Persky, DO; Unger, JM; Spier, CM
  • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B‑cell lymphomas: a randomised controlled trial (RICOVER-60)
    Pfreundschuh, M; Schubert, J; Ziepert, M
  • Excellent outcome of elderly patients with Favourable-prognosis DLBCL treated with 4 cycles CHOP/Chlip-14 plus 8 applications of Rituximab and a PET-based intensification strategy that includes involved-site radiotherapy (IS-RT): results of the first 120 patients of the OPTIMAL〉60 trial of the Dshnhl
    Pfreundschuh, M; Murawski, N; Christofyllakis, K
  • Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: Results of planned interim analysis of the first 187 patients with bulky disease treated in the optimal 〉60 study of the DSHNHL
    Pfreundschuh, M; Christofyllakis, K; Altmann, B
  • R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B‑cell lymphoma
    Lamy, T; Damaj, G; Soubeyran, P
  • Outcomes in refractory diffuse large B‑cell lymphoma: results from the international SCHOLAR-1 study
    Crump, M; Neelapu, SS; Farooq, U
  • Single agent oral selinexor exhibits durable responses in relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) of both GCB and non-GCB subtypes: the phase 2B SADAL study
    Maerevoet, M; Westin, J; Thieblemont, C
  • Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with Rrelapsed or refractory B‑cell non-hodgkin lymphomas
    Morschhauser, F; Salles, G; McKay, P
  • Axicabtagene ciloleucel CAR T‑cell therapy in refractory large B‑cell lymphoma
    Neelapu, SS; Locke, FL; Bartlett, NL
  • A comparison of one year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)
    Neelapu, SS; Locke, FL; Bartlett, NL
  • Chimeric antigen receptor T cells in refractory B‑cell lymphomas
    Schuster, SJ; Svoboda, J; Chong, EA
  • High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B‑NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort
    Abramson, JS; Palomba, ML; Gordon, LI
  • Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma
    Abramson, JS; McGree, B; Noyes, S
  • Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)
    Locke, FL; Westin, JR; Miklos, DB